A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281
 administered to participants with generalized myasthenia gravis (gMG) who have an
 insufficient clinical response to ongoing standard of care therapy.
Participants must be ≥18 years of age with a documented history of Generalized Myasthenia
 Gravis (gMG) and clinical signs/symptoms of gMG, not pregnant or breastfeeding, and no
 history of any neurologic disorder other than MG that might interfere with the accuracy of
 study assessments.

 Additional, more specific criteria are defined in the protocol.